Friedreich Ataxia (FA) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Friedreich Ataxia (FA) Emerging Therapy and TPP Insights

Thelansis's "Friedreich Ataxia (FA) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Friedreich Ataxia (FA) Overview

Friedreich's ataxia is an autosomal recessive neurodegenerative disorder caused by GAA trinucleotide repeat expansion in the FXN gene, reducing frataxin protein and impairing mitochondrial iron handling, leading to oxidative neuronal injury. It presents with progressive gait and limb ataxia, dysarthria, areflexia, sensory loss, and cardiomyopathy, with scoliosis and diabetes as common systemic features. Diagnosis combines genetic confirmation with neurophysiology and cardiac imaging; cardiomyopathy severity and functional decline mark disease progression. Omaveloxolone, an Nrf2 activator, is the first approved disease-modifying therapy targeting mitochondrial dysfunction. Supportive care includes physiotherapy, orthotics, and cardiac management. Annual multisystem surveillance is essential; multidisciplinary care focused on mobility, independence, and caregiver support underpins quality-of-life management.

Key Highlights

• FRDA is a rare, progressive neuromuscular disorder with significant neurological and cardiac burden
• US prevalence is expected to increase from 8.6K in 2025 to 9.3K by 2035 (0.7% CAGR)

Market Overview

• Germany market is projected to grow from $45M in 2025 to $135M by 2035 (11-12% CAGR)
• Growth driven by emerging disease-modifying and gene-targeted therapies, with high unmet need in current care

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• PTC Therapeutics
• Design Therapeutics, Inc.
• Larimar Therapeutics, Inc.
• Biogen
• Lexeo Therapeutics
• Solid Biosciences Inc.